<DOC>
	<DOCNO>NCT00737659</DOCNO>
	<brief_summary>In order avoid renal transplant rejection , immune system suppress . After renal transplant subject treat combination two four different type immunosuppressive drug . Theses drug efficient prevention renal transplant rejection . Still , cause side effect . Research renal transplant try find best treatment order avoid renal rejection one hand reduce much possible undesired adverse toxicity effect hand . Therapeutic efficacy onset adverse effect influence level mycophenolic acid ( MPA , active metabolite MMF , CellCept® ) . The primary objective study assess treatment superiority CellCept® Dose Adjustment treatment , base individual MPA concentration value monitor periodically , treatment CellCept® Fixed Dose ( standard care ) .</brief_summary>
	<brief_title>CellCept® Dose Adjustment Versus Fixed Dose ( Standard Care ) Renal Transplant Recipients</brief_title>
	<detailed_description>Patient randomize two treatment group 1:1 ratio . Both group treat drug usual treatment avoid renal transplant rejection . In one group CellCept® dose adjust base MPA concentration value monitor periodically ; second group treat CellCept® Fixed Dose ( base clinical judgment treat physician ) .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Male female subject , 18 70 year age time enrollment . Patient receive first second renal transplant . Patients 014 day post transplant . Patients capable understanding purpose risk study sign write informed consent participate comply requirement study . Women lactate , pregnant childbearing potential use reliable contraceptive method begin study drug therapy , therapy 4 month follow last dose study drug therapy . Patients severe diarrhea gastrointestinal disorder might interfere ability absorb oral medication , include diabetic patient previously diagnose diabetic gastroenteropathy . Patients history psychological illness condition interfere patient 's ability understand requirement study . Patients evidence active systemic infection require continue use antibiotic evidence HIV infection , presence chronic active hepatitis B ( HBsAg positive ) C. Current historic Panel Reactive Antibody ( PRA ) &gt; 50 % Positive crossmatch ( irrespective method ) . Cold ischemia time graft 30 hour . Patients receive investigational new drug within last three month time enrollment . Multiorgan recipient ( e.g . kidney pancreas ) previous transplant organ kidney . Patients know hypersensitivity MPA , ECMPS component formulation ( e.g . lactose ) . Patients thrombocytopenia ( &lt; 75,000/mm3 ) , absolute neutrophil count &lt; 1,500/mm3 , and/or leukocytopenia ( &lt; 2,500/mm3 ) , and/or hemoglobin &lt; 6 g/dL Screening Baseline . Patients history malignancy within last five year , except excise squamous basal cell carcinoma skin . Previous exposure ECMPS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Renal Transplant</keyword>
	<keyword>Renal</keyword>
	<keyword>Transplant</keyword>
	<keyword>MMF</keyword>
	<keyword>MPA</keyword>
	<keyword>Recipients</keyword>
</DOC>